Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria~2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia~3. Subjects experiencing an acute exacerbation of psychotic symptoms~Exclusion Criteria:~1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~2. Subjects with a current DSM-IV-TR Axis I diagnosis of:~   * Schizoaffective disorder~  * MDD~  * Bipolar disorder~  * Delirium, dementia, amnestic or other cognitive disorder~  * Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder~3. Subjects presenting with a first episode of schizophrenia~4. Other protocol specific inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): OPC-34712 0.25 mg arm
- 2 (Type: EXPERIMENTAL): OPC-34712 low-dose arm
- 3 (Type: EXPERIMENTAL): OPC-34712 mid-dose arm
- 4 (Type: EXPERIMENTAL): OPC-34712 high-dose arm
- 5 (Type: PLACEBO_COMPARATOR): None
- 6 (Type: ACTIVE_COMPARATOR): Aripiprazole arm

Based on this trial design, predict the completion outcome and termination type (if applicable).